TSE:ONC FY2025 EPS Estimate Lifted by Leede Financial

Oncolytics Biotech Inc. (TSE:ONC) – Investment analysts at Leede Financial increased their FY2025 earnings per share (EPS) estimates for Oncolytics Biotech in a research note issued on Monday, March 10th. Leede Financial analyst D. Loe now anticipates that the company will post earnings of ($0.40) per share for the year, up from their prior forecast of ($0.41). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Leede Financial also issued estimates for Oncolytics Biotech’s FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.38) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at ($0.13) EPS.

Separately, Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

Shares of TSE:ONC opened at C$0.91 on Thursday. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The stock has a market capitalization of C$70.14 million, a P/E ratio of -2.54 and a beta of 1.35. The business has a 50-day moving average price of C$1.10 and a two-hundred day moving average price of C$1.30. Oncolytics Biotech has a 1-year low of C$0.86 and a 1-year high of C$2.08.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.